Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
lomustine, Quantity: 10 mg
Bristol-Myers Squibb Australia Pty Ltd
Capsule, hard
Excipient Ingredients: mannitol; Gelatin; titanium dioxide; magnesium stearate; indigo carmine; butan-1-ol; Shellac; iron oxide black
Oral
20 capsules
(S4) Prescription Only Medicine
(1) Brain tumours (primary and secondary). (2) Hodgkin's disease (as secondary therapy). Lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. CeeNU containing combinations should be used as alternative therapy in the treatment of disseminated Hodgkin's Disease in patients refractory to other established treatment regimens.
Visual Identification: Capsule, white, marked in black with "CPL" above "3030" on the cap and "10MG" on the body; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
1991-09-30
CEENU ® _Lomustine (low-MUSS-teen)_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about CeeNU. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CeeNU against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CEENU IS USED FOR CeeNU is used to treat brain cancer. It may also be used to treat another type of cancer called Hodgkin's Disease. CeeNU belongs to a group of medicines called cytotoxic medicines. You may also hear of these being called chemotherapy medicines. CeeNU works by killing cancer cells. CeeNU is often used in combination with other medicines to treat your cancer. Your doctor may have prescribed CeeNU for another reason. Ask your doctor if you have any questions about why CeeNU has been prescribed for you. This medicine is available only with a doctor's prescription. Safety and effectiveness in children have not been established. BEFORE YOU TAKE CEENU DO NOT TAKE CEENU IF YOU HAVE A SEVERE ALLERGY TO CEENU OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET, Symptoms of an allergic reaction may include: • shortness of breath, wheezing, difficulty breathing or a tight feeling in your chest • swelling of the face, lips, tongue or other parts of the body • rash, itching, hives or flushed, red skin • dizziness or light headedness DO NOT TAKE CEENU IF YOU HAVE, OR HAVE HAD, ANY OF THE FOLLOWING MEDICAL CONDITIONS, UNLESS YOU HAVE DISCUSSED IT WITH YOUR DOCTOR: • blood disorder with a reduced number of red or white blood cells • liver problems • kidney problems • lung disease (including asthma) • heart problems (including a heart attack) • any other cancer • lowered immunity due to treatment with medicines such as cort Read the complete document
AU_PI_CeeNU_V9.0 1 AUSTRALIAN PRODUCT INFORMATION – CEENU ® (LOMUSTINE) 1 NAME OF THE MEDICINE Lomustine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Capsules containing 10 mg and 40 mg of lomustine. Lomustine (CeeNU) is an antitumour agent, cancer chemotherapeutic agent, cytotoxic agent and alkylating agent. Lomustine is a yellow powder, very slightly soluble in water (0.5mg/mL); slightly soluble in propylene glycol (0.7mg/mL) and polysorbate 80 (2.5mg/mL); soluble in absolute alcohol (70mg/mL). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Capsule containing 10mg lomustine are white, marked CPL 3030/10mg. Capsule containing 40mg lomustine are white/dark green, marked CPL 3031/40mg. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CeeNU may be used for the treatment of: 1. Brain tumours (primary and secondary). 2. Hodgkin's disease (as secondary therapy). Lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. CeeNU containing combinations should be used as alternative therapy in the treatment of disseminated Hodgkin's disease in patients refractory to other established treatment regimens. 4.2 DOSE AND METHOD OF ADMINISTRATION ADULTS The recommended dose of CeeNU is 130mg/m 2 as a single dose by mouth every 6 weeks. In individuals with compromised bone marrow function, the dose should be reduced to 100mg/m 2 every six weeks. A repeat course of CeeNU should not be given until circulating blood elements have returned to acceptable levels (platelets above 100,000/mm 3 , leucocytes above 4,000/mm 3 ). Blood counts should be monitored weekly and repeat courses should not be given before six weeks because the haematological toxicity is delayed and cumulative. Doses subsequent to the initial dose should be adjusted according to the haematologic response of the patient to the preceding dose. The hematologic response s Read the complete document